High Prevalence of Severe Depression in Mexican Patients Diagnosed with HIV Treated with Efavirenz and Atazanavir: Clinical Follow-Up at Four Weeks and Analysis of TPH2 SNPs.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Sandra Angélica Rojas-OsornioEscuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Francisco Guerra-CastilloUnidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología, "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.ORCID 0000-0002-3346-2004
Antonio Mata-MarínInfectious Diseases Department, Hospital de Infectología "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.ORCID 0000-0002-3701-9894
Vladimir Paredes-CervantesLaboratorio Central, Hospital de Especialidades "Dr. Antonio Fraga Mouret", "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.
Charmina Aguirre-AlvaradoUnidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología, "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.ORCID 0000-0003-1495-0245
Carolina Bekker-MéndezUnidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología, "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.ORCID 0000-0002-6161-1425
Gilberto Pérez-SánchezLaboratorio de Psicoinmunología, Dirección de Investigaciones en Neurociencias del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.ORCID 0000-0003-3878-0631
José Molina-LópezUnidad Periférica de Investigación Básica y Clínica en Enfermedades Infecciosas, Departamento de Salud Pública, División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Mónica Ortiz-MagandaUnidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología, "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.
Aurora Mercado-MéndezServicio de Higiene Mental del Hospital General, Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.
Emiliano Tesoro-CruzUnidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología, "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.ORCID 0000-0001-8877-8439
Funding
Instituto Mexicano del Seguro Social Fondo de Investigación en Salud (IMSS; FIS/IMSS/PROT/PRIO/18/071).
6 · The paper itself
Abstract
Efavirenz (EFV) causes neuropsychiatric effects such as anxiety, depression, and suicidal thoughts in people with HIV (PWH). Depressive disorders have been associated with the Tryptophan hydroxylase type 2 (
Indexed as
atazanavir/ritonavir (ATV/r)depressionefavirenz (EFV)people with HIV (PWH)tryptophan hydroxylase type 2 (TPH2)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
High Prevalence of Severe Depression in Mexican Patients Diagnosed with HIV Treated with Efavirenz and Atazanavir: Clinical Follow-Up at Four Weeks and Analysis of TPH2 SNPs. · full record | OpenQuestion